101805-0 |
DXA Calcaneus [Zscore] Bone density |
Zscore |
Bone |
Pt |
Qn |
|
|
ACTIVE |
Bone DXA Calcaneus [Z-score] Bone density |
|
ADD |
DefinitionDescription |
|
|
Zscore |
|
|
|
|
|
|
RAD |
|
101805-0 |
|
|
|
|
Both |
|
|
|
0 |
Bone DXA Z-score |
|
|
|
N |
|
BMD; BON; Den; DXA Z-score; Imaging; Point in time; QNT; Quan; Quant; Quantitative; RADIOLOGY; Random; Standard score; Z score; Z value; Z-score |
2.75 |
2.75 |
|
|
|
|
|
|
|
{Zscore} |
|
|
|
0 |
101806-8 |
Amyloid beta 42 peptide/Amyloid beta 40 peptide |
Ratio |
Plas |
Pt |
Qn |
LC/MS/MS |
|
DEPRECATED |
Deprecated Amyloid beta 42 peptide/Amyloid beta 40 peptide [Ratio] in Plasma by LC/MS/MS |
|
DEL |
DefinitionDescription |
|
|
ratio |
|
|
|
|
|
|
CHEM |
|
101806-8 |
|
LC/MS/MS |
|
|
Both |
|
|
|
0 |
Deprecated AL beta42/ABeta 40 Plas LC/MS/MS-Rto |
|
|
|
N |
|
A Beta42/A Beta 40 Ser; Ab40 peptide; Ab42 peptide; Abeta; ABeta 40; Abeta 42; ABeta 42/40; AL beta40; AL beta42; Alzheimer disease; Alzheimer's disease; B; Beta-amyloid; Chemistry; Pept; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; Ratios; Rto |
2.79 |
2.75 |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
101807-6 |
Malnutrition risk screen results indicator |
Type |
^Patient |
Pt |
Nom |
Nutrition and dietetics |
|
ACTIVE |
Malnutrition risk screen results indicator |
|
MIN |
DefinitionDescription |
|
|
|
|
�© Skipper A, Coltman A, Tomesko J, et al. Position of the Academy of Nutrition and Dietetics: Malnutrition (Undernutrition) Screening Tools for All Adults. J Acad Nutr Diet. Apr 2020;120(4):709-713. doi:10.1016/j.jand.2019.09.011 Used with Permission |
|
|
|
|
NUTRITION&DIETETICS |
|
101807-6 |
|
Nutrition and dietetics |
|
|
Observation |
|
|
|
0 |
Malnut risk scn resu |
|
|
|
N |
|
Malnut risk scn resu; Nominal; Nutr+diet; Nutrition+Dietetics; Point in time; Random; Scn; Scr; Scrn; SDOH; Typ |
2.79 |
2.75 |
|
|
|
|
�© Skipper A, Coltman A, Tomesko J, et al. Position of the Academy of Nutrition and Dietetics: Malnutrition (Undernutrition) Screening Tools for All Adults. J Acad Nutr Diet. Apr 2020;120(4):709-713. doi:10.1016/j.jand.2019.09.011 Used with Permission |
|
|
|
|
|
Release 2.79: FORMULA: Removed incorrect value from formula; |
0 |
101808-4 |
Xylazine |
MCnc |
Urine |
Pt |
Qn |
Confirm |
|
ACTIVE |
Xylazine [Mass/volume] in Urine by Confirmatory method |
|
ADD |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
101808-4 |
|
Confirm |
|
|
Both |
|
|
|
0 |
Xylazine Ur Cfm-mCnc |
|
|
|
N |
|
Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; GCMS; LC/MS/MS; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; Tranq; UA; UR; Urn |
2.75 |
2.75 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
101809-2 |
Xylazine |
PrThr |
Urine |
Pt |
Ord |
Confirm |
|
ACTIVE |
Xylazine [Presence] in Urine by Confirmatory method |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
101809-2 |
|
Confirm |
|
|
Both |
|
|
|
0 |
Xylazine Ur Ql Cfm |
|
|
|
N |
|
Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; GCMS; LC/MS/MS; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Tranq; UA; UR; Urn |
2.75 |
2.75 |
|
|
|
|
|
|
|
|
|
|
|
0 |
10181-6 |
Symptoms & diseases |
Hx |
Urinary tract |
Pt |
Nar |
|
|
ACTIVE |
History of Urinary tract disorders Narrative |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
H&P.HX |
|
10181-6 |
|
|
|
|
|
|
|
|
0 |
Hx of Urinary disorders |
|
|
|
|
|
H+P; H+P.HX; History; Narrative; P prime; Point in time; Random; Report; Sx; Symp + dis |
2.56 |
1.0i |
|
|
|
|
|
|
|
|
|
|
Removed "History of" from Component, changed Property from "Find" to "Hx", and removed "Reported" Method per 8/2015 Clinical LOINC Committee decision |
0 |
101810-0 |
Xylazine/Creatinine |
MRto |
Urine |
Pt |
Qn |
Confirm |
|
ACTIVE |
Xylazine/Creatinine [Mass Ratio] in Urine by Confirmatory method |
|
ADD |
DefinitionDescription |
|
|
ng/mg |
|
|
|
|
|
|
DRUG/TOX |
|
101810-0 |
|
Confirm |
|
|
Both |
|
|
|
0 |
Xylazine/Creat Ur Cfm |
|
|
|
N |
|
Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; CR; Crea; Creat; DRUG/TOXICOLOGY; Drugs; GCMS; LC/MS/MS; Mass concentration ratio; Mass ratio; MCRto; Point in time; QNT; Quan; Quant; Quantitative; Random; Tranq; UA; UCr; UR; Urn |
2.75 |
2.75 |
|
|
|
|
|
|
|
ng/mg |
|
|
|
0 |
101811-8 |
2,6-dimethylaniline |
PrThr |
Urine |
Pt |
Ord |
Confirm |
|
ACTIVE |
2,6-dimethylaniline [Presence] in Urine by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
101811-8 |
|
Confirm |
|
|
Both |
|
|
|
0 |
2,6-dimethylaniline Ur Ql Cfm |
|
|
|
N |
|
2,6-XYLIDINE; 2-Amino-m-xylene; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; GCMS; II; LC/MS/MS; Ordinal; o-Xylidine; Point in time; PR; QL; Qual; Qualitative; Random; Screen; UA; UR; Urn |
2.77 |
2.75 |
|
|
|
|
|
|
|
|
|
|
|
0 |
101812-6 |
2,6-dimethylaniline/Creatinine |
MRto |
Urine |
Pt |
Qn |
Confirm |
|
ACTIVE |
2,6-dimethylaniline/Creatinine [Mass Ratio] in Urine by Confirmatory method |
|
ADD |
DefinitionDescription |
|
|
ng/mg |
|
|
N/A |
|
|
|
DRUG/TOX |
|
101812-6 |
|
Confirm |
|
|
Both |
|
|
|
0 |
2,6-dimethylaniline/Creat Ur Cfm |
|
|
|
N |
|
2,6-XYLIDINE; 2-Amino-m-xylene; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; CR; Crea; Creat; DRUG/TOXICOLOGY; Drugs; GCMS; II; LC/MS/MS; Mass concentration ratio; Mass ratio; MCRto; o-Xylidine; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UCr; UR; Urn |
2.75 |
2.75 |
|
|
|
|
|
|
|
ng/mg |
|
|
|
0 |
101813-4 |
2,6-dimethylaniline |
MCnc |
Urine |
Pt |
Qn |
Confirm |
|
ACTIVE |
2,6-dimethylaniline [Mass/volume] in Urine by Confirmatory method |
|
ADD |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
101813-4 |
|
Confirm |
|
|
Both |
|
|
|
0 |
2,6-dimethylaniline Ur Cfm-mCnc |
|
|
|
N |
|
2,6-XYLIDINE; 2-Amino-m-xylene; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; GCMS; II; LC/MS/MS; Level; Mass concentration; o-Xylidine; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.75 |
2.75 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
101814-2 |
BK virus DNA |
ACnc |
CSF |
Pt |
Qn |
Probe.amp.tar |
|
ACTIVE |
BK virus DNA [Units/volume] (viral load) in Cerebral spinal fluid by NAA with probe detection |
|
ADD |
DefinitionDescription |
|
|
IU/mL |
|
|
|
|
|
|
MICRO |
|
101814-2 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
BKV DNA CSF NAA+probe-aCnc |
|
|
|
N |
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; Arbitrary concentration; BKV; Cerebral spinal fluid; Cerebrospinal Fl; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; PCR; Point in time; Polymerase chain reaction; Probe amp; Probe with ampification; Probe with target amplification; QBR; QNT; Quan; Quant; Quantitative; Random; SDA; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid; Strand Displacement Amplification; TMA; Transcription mediated amplification; Viral load |
2.75 |
2.75 |
|
|
|
|
|
|
|
[IU]/mL |
|
|
|
0 |
101815-9 |
Cytomegalovirus DNA |
ACnc |
CSF |
Pt |
Qn |
Probe.amp.tar |
|
ACTIVE |
Cytomegalovirus DNA [Units/volume] (viral load) in Cerebral spinal fluid by NAA with probe detection |
|
ADD |
DefinitionDescription |
|
|
IU/mL |
|
|
|
|
|
|
MICRO |
|
101815-9 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
CMV DNA CSF NAA+probe-aCnc |
|
|
|
N |
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; Arbitrary concentration; Cerebral spinal fluid; Cerebrospinal Fl; CMV; Cytomegalo virus; Cytomgal; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; HHV-5; Human Herpesvirus-5; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; PCR; Point in time; Polymerase chain reaction; Probe amp; Probe with ampification; Probe with target amplification; QBR; QNT; Quan; Quant; Quantitative; Random; SDA; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid; Strand Displacement Amplification; TMA; Transcription mediated amplification; Viral load |
2.75 |
2.75 |
|
|
|
|
|
|
|
[IU]/mL |
|
|
|
0 |
101816-7 |
Cytomegalovirus DNA |
ACnc |
Urine |
Pt |
Qn |
Probe.amp.tar |
|
ACTIVE |
Cytomegalovirus DNA [Units/volume] (viral load) in Urine by NAA with probe detection |
|
ADD |
DefinitionDescription |
|
|
IU/mL |
|
|
|
|
|
|
MICRO |
|
101816-7 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
CMV DNA Ur NAA+probe-aCnc |
|
|
|
N |
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; Arbitrary concentration; CMV; Cytomegalo virus; Cytomgal; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; HHV-5; Human Herpesvirus-5; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; PCR; Point in time; Polymerase chain reaction; Probe amp; Probe with ampification; Probe with target amplification; QBR; QNT; Quan; Quant; Quantitative; Random; SDA; Strand Displacement Amplification; TMA; Transcription mediated amplification; UA; UR; Urn; Viral load |
2.75 |
2.75 |
|
|
|
|
|
|
|
[IU]/mL |
|
|
|
0 |
101817-5 |
Epstein Barr virus DNA |
ACnc |
CSF |
Pt |
Qn |
Probe.amp.tar |
|
ACTIVE |
Epstein Barr virus DNA [Units/volume] (viral load) in Cerebral spinal fluid by NAA with probe detection |
|
ADD |
DefinitionDescription |
|
|
IU/mL |
|
|
|
|
|
|
MICRO |
|
101817-5 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
EBV DNA CSF NAA+probe-aCnc |
|
|
|
N |
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; Arbitrary concentration; Cerebral spinal fluid; Cerebrospinal Fl; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; EBV; Epstn; HHV-4; human herpesvirus 4; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; Mono; Mononucleosis; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; PCR; Point in time; Polymerase chain reaction; Probe amp; Probe with ampification; Probe with target amplification; QBR; QNT; Quan; Quant; Quantitative; Random; SDA; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid; Strand Displacement Amplification; TMA; Transcription mediated amplification; Viral load |
2.75 |
2.75 |
|
|
|
|
|
|
|
[IU]/mL |
|
|
|
0 |
101818-3 |
Herpes virus 6 DNA |
ACnc |
CSF |
Pt |
Qn |
Probe.amp.tar |
|
ACTIVE |
Herpes virus 6 DNA [Units/volume] in Cerebral spinal fluid by NAA with probe detection |
|
ADD |
DefinitionDescription |
|
|
IU/mL |
|
|
|
|
|
|
MICRO |
|
101818-3 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
HHV6 DNA CSF NAA+probe-aCnc |
|
|
|
N |
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; Arbitrary concentration; Cerebral spinal fluid; Cerebrospinal Fl; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; Herpesvirus; HHV; HHV6; HHV-6; Human herpes virus; Human herpes virus type 6; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; PCR; Point in time; Polymerase chain reaction; Probe amp; Probe with ampification; Probe with target amplification; QBR; QNT; Quan; Quant; Quantitative; Random; SDA; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid; Strand Displacement Amplification; TMA; Transcription mediated amplification; Viral load |
2.75 |
2.75 |
|
|
|
|
|
|
|
[IU]/mL |
|
|
|
0 |
101819-1 |
Nutritional assessment for malnutrition status |
Find |
^Patient |
Pt |
Nom |
|
|
ACTIVE |
Nutritional assessment for malnutrition status |
|
MIN |
DefinitionDescription |
|
|
|
|
�© 2020, Nutrition Terminology Reference Manual (eNCPT): Dietetics Language for Nutrition Care. Academy of Nutrition and Dietetics. Used with permission |
|
|
|
|
CLIN.RISK |
|
101819-1 |
|
|
|
|
Observation |
|
|
|
0 |
Nut assess malnut status |
|
|
|
N |
|
CLIN; CLIN.RISK; Finding; Findings; Nominal; Nut assess malnut status; Point in time; Random; SDOH |
2.79 |
2.75 |
|
|
|
|
�© 2020, Nutrition Terminology Reference Manual (eNCPT): Dietetics Language for Nutrition Care. Academy of Nutrition and Dietetics. Used with permission |
|
|
|
|
|
Release 2.79: FORMULA: Removed incorrect value from formula; Release 2.77: EXTERNAL_COPYRIGHT_LINK: Set Copyright; |
0 |
10182-4 |
Travel |
Hx |
^Patient |
Pt |
Nar |
|
|
ACTIVE |
History of Travel Narrative |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
H&P.HX |
|
10182-4 |
|
|
|
|
|
|
|
|
0 |
Hx of Travel |
|
|
|
|
|
H+P; H+P.HX; History; Narrative; P prime; Point in time; Random; Report |
2.56 |
1.0i |
|
|
|
|
|
|
|
|
|
|
Removed "History of" from Component, changed Property from "Find" to "Hx", and removed "Reported" Method per 8/2015 Clinical LOINC Committee decision |
0 |
101820-9 |
Preimplantation targeted mutation analysis |
Find |
^Embryo |
Pt |
Doc |
Molgen |
|
ACTIVE |
Preimplantation targeted mutation analysis in Embryo by Molecular genetics method |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MOLPATH.MUT |
|
101820-9 |
|
Molgen |
|
|
Both |
|
|
|
0 |
Preimplantation Mut Anl Embryo |
|
|
|
N |
|
Document; Finding; Findings; Molecular genetics; Molecular pathology; MOLPATH; MOLPATH.MUTATIONS; Mut; Mut Anl; Mutations; PCR; Point in time; Random |
2.75 |
2.75 |
|
|
|
|
|
|
|
|
|
|
|
0 |
101822-5 |
Human papilloma virus cytology and high-risk genotypes panel |
- |
Cvx |
Pt |
- |
|
|
ACTIVE |
Human papilloma virus cytology and high-risk genotypes panel - Cervix |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.MICRO |
|
101822-5 |
|
|
|
|
Order |
|
|
|
0 |
HPV Cyto HR genotypes Pnl Cvx |
|
|
|
N |
|
Cervix; Genital tract; Genital warts; HPV; HPV Cyto HR genotypes Pnl; Human papillomavirus; Microbiology; Pan; PANEL.MICROBIOLOGY; Panl; Pnl; Point in time; Random |
2.76 |
2.75 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
101823-3 |
Apolipoprotein C-III |
PrThr |
Ser/Plas |
Pt |
Doc |
Isoelectric focusing |
|
ACTIVE |
Apolipoprotein C-III [Presence] in Serum or Plasma by Isoelectric focusing |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
101823-3 |
|
Isoelectric focusing |
|
|
Both |
|
|
|
0 |
Apo C-III SerPl IEF |
|
|
|
N |
|
3; APO; Apo C; Apo C-III; Apolipo; Apolipoprot; Apolipoprotein C3; Apolipoproteins; Chemistry; Document; IEF; Pl; Plasma; Plsm; Point in time; PR; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.75 |
2.75 |
|
|
|
|
|
|
|
|
|
|
|
0 |
101824-1 |
Aspartylglucosaminidase |
CCnt |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Aspartylglucosaminidase [Enzymatic activity/mass] in Serum or Plasma |
|
MAJ |
DefinitionDescription |
|
|
nmol/mg |
|
|
|
|
|
|
CHEM |
|
101824-1 |
|
|
|
|
Both |
|
|
|
0 |
AGA SerPl-cCnt |
|
|
|
N |
|
4-l-aspartylglycosylamine amido hydrolase; 4-l-aspartylglycosylamine amidohydrolase; AGA; Aspartylglucosaminuria; Aspartylglucosylamine deaspartylase; Aspartylglucosylaminidase; Catalytic Content; Chemistry; Glycosylasparaginase; N4-(beta-n-acetylglucosaminyl)-l-asparaginase; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.76 |
2.75 |
|
|
|
|
|
|
|
nmol/mg |
|
|
|
0 |
101825-8 |
Brushite crystals |
SatFr |
Urine |
24H |
Qn |
|
|
ACTIVE |
Brushite crystals [Saturation Fraction] in 24 hour Urine |
|
NAM |
DefinitionDescription |
|
|
kJ/mol |
|
|
|
|
|
|
CHEM |
|
101825-8 |
|
|
|
|
Both |
|
|
|
0 |
Brushite Cry 24h SatFr Ur |
|
|
|
N |
|
1 day; 24 hours; 24HR; Chemistry; Crys; Cryst; Crystal; Percent; QNT; Quan; Quant; Quantitative; Relative Supersaturation; RS; Saturation Fraction; UA; UR; Urn |
2.76 |
2.75 |
|
|
|
|
|
|
|
kJ/mol |
|
|
|
0 |
101826-6 |
Sodium Urate crystals |
SatFr |
Urine |
24H |
Qn |
|
|
ACTIVE |
Sodium Urate crystals [Saturation Fraction] in 24 hour Urine |
|
NAM |
DefinitionDescription |
|
|
kJ/mol |
|
|
|
|
|
|
CHEM |
|
101826-6 |
|
|
|
|
Both |
|
|
|
0 |
Na Urate cry 24h SatFr Ur |
|
|
|
N |
|
1 day; 24 hours; 24HR; Chemistry; Crys; Cryst; Crystal; Monosodium Urate; Na; Na Urate; Na Urate cry; Na+; NaU; Percent; QNT; Quan; Quant; Quantitative; Relative Supersaturation; RS; Saturation Fraction; UA; UR; Urates; Uric acid; Urn |
2.76 |
2.75 |
|
|
|
|
|
|
|
kJ/mol |
|
|
|
0 |
101827-4 |
Urate crystals |
SatFr |
Urine |
24H |
Qn |
|
|
ACTIVE |
Urate crystals [Saturation Fraction] in 24 hour Urine |
|
NAM |
DefinitionDescription |
|
|
kJ/mol |
|
|
|
|
|
|
CHEM |
|
101827-4 |
|
|
|
|
Both |
|
|
|
0 |
Urate cry 24h SatFr Ur |
|
|
|
N |
|
1 day; 24 hours; 24HR; Chemistry; Crys; Cryst; Crystal; Percent; QNT; Quan; Quant; Quantitative; Relative Supersaturation; RS; Saturation Fraction; UA; UR; Urates; Uric acid; Urn |
2.76 |
2.75 |
|
|
|
|
|
|
|
kJ/mol |
|
|
|
0 |
101828-2 |
Synthetic glucocorticoid panel |
- |
Ser/Plas |
Pt |
- |
|
|
ACTIVE |
Synthetic glucocorticoid panel - Serum or Plasma |
|
MAJ |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.CHEM |
|
101828-2 |
|
|
|
|
Order |
|
|
|
0 |
Syn Glucocorticoid Pnl SerPl |
|
|
|
N |
|
Chemistry; Pan; PANEL.CHEMISTRY; Panl; Pl; Plasma; Plsm; Pnl; Point in time; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Syn Glucocorticoid Pnl |
2.76 |
2.75 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |